Trials / Terminated
TerminatedNCT04668521
Multifactorial Risk Assessment for Breast & Ovarian Cancer Risk Detection
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 215 (actual)
- Sponsor
- Aspira Women's Health · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The objective of this project is to validate a next-generation assay that utilizes both the protein biomarkers of our already established ovarian cancer risk assessment combined with a molecular profile in both germline and early somatic detection.
Conditions
- Adnexal Mass
- Germline BRCA1 Gene Mutation
- Germline BRCA2 Gene Mutation
- Hereditary Breast and Ovarian Cancer
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | OVA360 | Multifactorial Risk Assessment for Breast \& Ovarian Cancer Risk Detection |
Timeline
- Start date
- 2020-05-04
- Primary completion
- 2023-12-15
- Completion
- 2023-12-15
- First posted
- 2020-12-16
- Last updated
- 2023-12-26
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT04668521. Inclusion in this directory is not an endorsement.